Brainomix and Bridge Biotherapeutics, Inc. Announce Partnership to Utilize Brainomix’ AI-Powered e-ILD Software for Automated Assessment of Idiopathic Pulmonary Fibrosis (IPF) – QNT Press Release


  • The partnership will focus on quantitative analysis of imaging data by Brainomix AI software (e-ILD) within the Phase 2 Study of novel autotaxin inhibitor, BBT-877, in idiopathic pulmonary fibrosis (IPF)

OXFORD, England, Sept. 7, 2022 /PRNewswire/ — Brainomix, the AI-powered medtech solutions company, and Bridge Biotherapeutics, Inc., a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, today announced a new partnership to deliver quantitative imaging biomarker analysis within the Phase 2 study of novel autotaxin inhibitor BBT-877, which has been designed to evaluate the safety, tolerability and efficacy of BBT-877 in Idiopathic Pulmonary Fibrosis (IPF).

Under the partnership, Brainomix will leverage its e-ILD technology (automated artificial intelligence software) which has been trained to process high resolution chest CT (HRCT) data in patients with Interstitial Lung Diseases, including IPF and other conditions that cause progressive pulmonary fibrosis. Both companies aim to collect high-quality imaging data which will be used to explore the efficacy of BBT-877, and to demonstrate the value that Brainomix AI-powered imaging biomarkers offer as new endpoints for future IPF clinical trials.

Clinical trials in IPF commonly rely on serial physiological measurement of forced vital capacity (FVC) as trial endpoints, which can be highly variable from day-to-day for any individual patient. Automated AI-powered quantitative imaging has the potential to significantly improve trial design, improve the chances of identifying a positive treatment response and accelerate the translation of new treatments into clinical practice. Using proprietary and patented objective imaging biomarkers, and tracking changes over time, Brainomix will provide Bridge Biotherapeutics with valuable insights and additional data on the . ..

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center